Heart Disease News and Research

Latest Heart Disease News and Research

Bayer receives FDA approval for Gadavist Injection

Bayer HealthCare Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration has approved Gadavist Injection, a macrocyclic gadolinium-based contrast agent, for intravenous use in diagnostic magnetic resonance imaging in adults and children to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.

14 Mar 2011

OrbusNeich launches CE marked Azule Cobalt Chromium Stent

OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent. The Azule Stent combines the proven stent design of its predecessor, the company's Blazer™ Cobalt Chromium Stent, with a delivery system with enhanced crossability and flexible deliverability.

14 Mar 2011

Gamida to distribute Health Robotics' CytoCare, i.v.STATION, i.v.SOFT technologies in Israel

Health Robotics today announced that it recently signed an exclusive distribution agreement for its CytoCare, i.v.STATION, and i.v.SOFT world-leading technologies with Israel-based medical technology leader Gamida MedEquip Ltd.

14 Mar 2011

Omthera to fund Epanova Phase 3 development with $33.9 million in Series B funding

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.

14 Mar 2011

Medtronic launches Contour 3D Annuloplasty Ring for treatment of tricuspid valve disease

Medtronic, Inc. today announced the global launch of a new tricuspid ring for the treatment of tricuspid valve disease. Called the Contour 3D™ Annuloplasty Ring, the device is designed to restore normal valve function by remodeling the natural valve's shape and size. The Contour 3D Ring is approved for use in the U.S., Europe and several other countries.

14 Mar 2011

Indium oxine in development at Positron's Crown Point facility

Positron Corporation a molecular imaging company announced today that it is developing indium oxine, a radiopharmaceutical widely used for the radiolabeling of blood elements. This project signifies Positron's entrance into direct radiopharmaceutical manufacturing and sales; indium oxine is the first new product in development at Positron's research, development and manufacturing facility in Crown Point, Indiana.

14 Mar 2011

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD).

14 Mar 2011

Fysicon to customize Merge solutions for BeNeLux market

Merge Healthcare Incorporated, a global corporation dedicated to health IT interoperability solutions, today announced the expansion of its existing software relationship with Fysicon, the dominant Dutch distributor of medical imaging solutions for radiology and cardiology. Fysicon will customize Merge solutions to improve its specific portfolio of image management products for the BeNeLux market

14 Mar 2011

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been dosed in its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega-3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

14 Mar 2011

Life Technologies receives FDA 510(k) clearance for StemPro MSC SFM device

Life Technologies Corporation today announced it has received FDA 510(k) clearance for StemPro MSC SFM – a first for this next-generation stem cell culture medium that is now cleared as a medical device and satisfies a crucial requirement for researchers involved in clinical trials in the United States.

14 Mar 2011

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

BioInvent International AB announces today the dosing of the first patient in the phase II study of the Company's antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with acute coronary syndrome.

14 Mar 2011

Hospice and Palliative care

The word hospice originated from the Latin hospitium, which means "to host or offer a place of shelter." In 2009, an estimated 1.56 million patients, more than 40 percent of deaths, received hospice services in the United States.

14 Mar 2011

OICR welcomes Government of Canada's announcement of support for cancer control

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research today welcomed the Government of Canada's announcement of support for cancer control with a renewal of the mandate of the Canadian Partnership Against Cancer for five years and $250 million in funding.

14 Mar 2011

U-M's CoreValve trial to offer less invasive approach for patients with aortic stenosis

The University of Michigan Cardiovascular Center, a leader in heart valve replacement, will participate in a national clinical trial to offer patients a less invasive approach to replacing diseased aortic valves.

14 Mar 2011

HDL cholesterol structure finding could help explain cardioprotective effects

University of Cincinnati researchers have determined the structure of human HDL cholesterol and say the finding could help explain how this "fat packet" protects against cardiovascular diseases, including heart attack and stroke.

14 Mar 2011

Novel biomarkers may aid in diagnosis and management of asthma, COPD

Four novel biomarkers have been identified which may aid in the diagnosis and management of asthma and chronic obstructive pulmonary disease, according to a study conducted by researchers in Australia, who determined the biomarkers may be used in different combinations to successfully identify patients with either of the airway diseases.

14 Mar 2011

Test that measures destruction of lung air sacs, could help prevent progression of emphysema

During a regular annual physical exam, blood is usually drawn to check the health of a person's heart, kidneys and liver. Now, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center say a blood test that detects the early development of emphysema -- well before symptoms occur -- may someday also be offered.

12 Mar 2011

Coffee reduces stroke risk: Study

A new study involving nearly 35,000 women published Thursday in Stroke: Journal of the American Heart Association suggests that drinking coffee may lower the risk of stroke.

12 Mar 2011

Acupuncture for menopausal hot flashes: Study

According to a new study, women who suffer from hot flashes and other uncomfortable symptoms of menopause may be able to find relief through acupuncture. These symptoms plague menopausal women and usual therapy for it is hormone replacement therapy but that has its own problems including an increased risk of coronary heart disease, stroke and breast cancer.

12 Mar 2011

FDA approves Lantheus Medical Imaging's SPA for flurpiridaz F-18 Phase 3 trial in coronary artery disease

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design and planned analysis of a Phase 3 clinical trial for the assessment of myocardial perfusion using Positron Emission Tomography (PET) imaging of flurpiridaz F-18 in patients with suspected or known coronary artery disease (CAD).

11 Mar 2011

Heart Disease News and Research

Latest Heart Disease News and Research

Bayer receives FDA approval for Gadavist Injection

OrbusNeich launches CE marked Azule Cobalt Chromium Stent

Gamida to distribute Health Robotics' CytoCare, i.v.STATION, i.v.SOFT technologies in Israel

Omthera to fund Epanova Phase 3 development with $33.9 million in Series B funding

Medtronic launches Contour 3D Annuloplasty Ring for treatment of tricuspid valve disease

Indium oxine in development at Positron's Crown Point facility

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

Fysicon to customize Merge solutions for BeNeLux market

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Life Technologies receives FDA 510(k) clearance for StemPro MSC SFM device

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

Hospice and Palliative care

OICR welcomes Government of Canada's announcement of support for cancer control

U-M's CoreValve trial to offer less invasive approach for patients with aortic stenosis

HDL cholesterol structure finding could help explain cardioprotective effects

Novel biomarkers may aid in diagnosis and management of asthma, COPD

Test that measures destruction of lung air sacs, could help prevent progression of emphysema

Coffee reduces stroke risk: Study

Acupuncture for menopausal hot flashes: Study

FDA approves Lantheus Medical Imaging's SPA for flurpiridaz F-18 Phase 3 trial in coronary artery disease

Forensics and toxicology - Industry Focus eBook eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Heart Disease News and Research

Latest Heart Disease News and Research

Forensics and toxicology - Industry Focus eBook eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in